ArticleSexual medicine2025
Psychometric evaluation and measurement invariance of the Sexual and Relationship Distress Scale in cancer and nonclinical general reproductive-age populations.
Article in Sexual medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Sexual and Relationship Distress Scale (SaRDS) is a validated instrument developed in English to assess intra-personal and inter-personal distress experienced by individuals and their partners in the context of sexual dysfunction. However, it has not yet been translated into Chinese nor psychometrically evaluated within Chinese clinical cancer and nonclinical populations. Objective: This study aimed to translate the SaRDS into Chinese and assess its psychometric properties and measurement invariance across different populations (colorectal cancer [CRC] patients vs. nonclinical general reproductive-age adults) and across gender groups (male vs. female). Methods: Three phases were undertaken: (a) transcultural adaptation, (b) pre-testing, and (c) psychometric evaluation. Transcultural adaptation included translations and expert panels, the pre-testing was conducted in 20 participants. The psychometric evaluation was tested among 486 CRC patients and 536 nonclinical general reproductive-age populations. Outcomes: The Chinese version of the SaRDS was consistent with the original version, including 30 items and 14 factors. Results: Confirmatory factor analysis supported the 14-factor structure of the original SaRDS construct. The composite reliability and the average variance extracted indicated the SaRDS had good convergent validity. Measurement invariance analyses indicated that the factor structure, factor loadings, and item intercepts of the SaRDS were invariant across CRC and nonclinical general populations, as well as across gender groups. The correlation of SaRDS with the Arizona Sexual Experience Scale and the Quality of Relationship Index showed good criterion-related validity. Moreover, the SaRDS and subscales had high internal consistency. Clinical implications: The Chinese version of the SaRDS is a psychometrically robust tool suitable for evaluating individual and relationship distress related to sexual dysfunction among clinical cancer and nonclinical general populations. The 14 domains provided by the SaRDS enable clinicians to identify specific areas of distress, facilitating accurate assessment and tailored interventions for individuals and couples experiencing sexual difficulties. Strengths and limitations: This study provides the first evidence of measurement invariance of the SaRDS across cancer patients, nonclinical general populations, and gender groups. However, due to its cross-sectional design, future longitudinal studies are needed to further examine the temporal stability and measurement invariance over time. Conclusion: Our findings suggest that the Chinese version of the SaRDS is a reliable, valid, and psychometrically sound instrument for assessing sexual and relationship distress in clinical cancer and nonclinical reproductive-age populations. Its demonstrated measurement invariance across populations and genders supports its broad applicability in clinical practice and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.